[1] Jaffe E, Harris N, Stein H, et al.World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press,2001:171-175.
[2] Morton LM, Wang SS, Devesa SS, et al.Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001[J]. Blood,2006,107(1):265-276.
[3] 李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布国内多中心性病例10002例分析[J]. 诊断学理论与实践,2012,11(2):111-115.
[4] 李海明, 王春燕, 于宝丹, 等. 分析弥漫大B细胞淋巴瘤的临床特点及其预后相关因素探究[J]. 中国实用医药,2016,11(11):83-84.
[5] 唐晓钰, 庞辉. 结外弥漫大B细胞淋巴瘤的发病及生存研究进展[J]. 医学综述,2016,22(15):2972-2974.
[6] Demircay E, Hornicek FJ Jr, Mankin HJ, et al.Malignant lymphoma of bone: a review of 119 patients[J]. Clin Orthop Relat Res,2013,471(8):2684-2690.
[7] Beal K, Allen L, Yahalom J.Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients[J]. Cancer,2006,106(12):2652-2656.
[8] 张利娟, 王凤玮.弥漫大B细胞淋巴瘤的治疗进展[J]. 中华临床医师杂志(电子版),2014,8(11):2127-2132.
[9] Haycocks NG, Zhao XF.Large B-cell lymphoma with an unusual infiltrating pattern: report of two cases[J]. Int J Clin Exp Pathol,2010,3(8):815-821.
[10] 孙广伟, 李华章, 王本锋, 等. EGFR单克隆抗体西妥昔单抗联合化疗治疗胃癌的临床应用价值[J]. 西部医学,2013,25(4):528-530,533.
[11] Coiffier B, Lepage E, Briere J, et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med,2002,346(4):235-242.
[12] Pfreundschuh M, Trümper L, Osterborg A, et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group[J]. Lancet Oncol,2006,7(5):379-391.
[13] Pfreundschuh M, Kloess M, Zeynalova S, et al.Six vs. eight cycles of bi-weekly CHOP-14 with or without ritu-ximab for elderly patients with diffuse large-B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group(DSHNHL)[J]. Blood,2006,108:205.
[14] Ott G, Ziepert M, Klapper W, et al.Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL[J]. Blood,2010,116(23):4916-4925.
[15] 赵世华, 肖秀斌, 仲凯励, 等. 120例初治、年轻、中高/高危弥漫大B细胞淋巴瘤的临床分析[J]. 现代医学生物进展,2016,16(4):683-687. |
